Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer

Inclusion Criteria: I1. Male or female patients aged ≥ 18 years at time of informed consent signature. I2. Patient with histologically confirmed diagnosis of metastatic clear cell renal cell carcinoma (mccRCC) previously treated by at least 2 lines of therapy in the advanced/metastatic setting including at least 1 line of anti-VEGFR and 1 line of immunotherapy. I3. Patient with documented radiological disease progression at the time of inclusion with measurable disease as per RECIST v1.1. I4. Patient with PSMA-PET positive lesions (68Ga-PSMA-PET): * For patient with only extrahepatic disease: ≥ 50% of positive extrahepatic metastatic lesions * For patient with both extra-hepatic and liver metastasis: ≥ 50% of positive extrahepatic metastatic lesions and ≥ 80 % of positive supracentimetric liver metastatic lesions. * For patient with only liver metastatic lesions: ≥ 80 % of positive supracentimetric lesions. I5. Life expectancy ≥ 3 months. I6. Eastern Cooperative Oncology Group performance status 0, 1 or 2. I7. Demonstrate adequate organ function as defined in the protocol. I8. Women of child-bearing potential must have a negative urine pregnancy test at screening (within 72 hours prior C1D1) and must agree to use 1 effective form of contraception from the time of the treatment period and of the negative pregnancy test up to 6 months after the last administration of study drug. Effective forms of contraception are listed in the protocol. I9. Fertile males must use hi…